Table 2 Association of TGFBI methylation and clinicopathologic variables in 40 ovarian cancer patients
From: TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer
Clinicopathologic characteristics | Number (n) | Methylation (%) | P value |
|---|---|---|---|
Age at diagnosis | Â | Â | Â |
< 50 years | 14 | 9 (64.3) | 0.3932 |
≥50 years | 26 | 20 (76.9) |  |
Histological type | Â | Â | Â |
Serous adenocarcinoma | 20 | 16 (80.0) | 0.4814 |
Mucinous adenocarcinoma | 13 | 9 (69.2) | Â |
Endometrioid adenocarcinoma | 7 | 4 (57.1) | Â |
Tumor stage | Â | Â | Â |
I | 6 | 2 (33.3) | 0.0661 |
II | 10 | 8 (80.0) | Â |
III | 24 | 19 (79.2) | Â |
Histological grade | Â | Â | Â |
G1 | 4 | 2 (40.0) | 0.5532 |
G2 | 7 | 5 (71.4) | Â |
G3 | 29 | 22 (75.9) | Â |
Lymphatic metastasis | Â | Â | Â |
No | 18 | 13 (72.2) | 0.9716 |
Yes | 22 | 16 (72.7) | Â |